94. Primary sclerosing cholangitis Clinical trials / Disease details


Clinical trials : 148 Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005558-21-GB
(EUCTR)
25/03/201506/01/2015A phase 2a trial to evaluate the safety and tolerability of LUM001 in subjects with Primary Sclerosing Cholangitis (PSC) during 14 weeks of treatment.A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Primary Sclerosing Cholangitis (PSC) - CAMEO STUDY Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology.PSC is characterized by inflammation and fibrosis of the intra- and extrahepatic biliary tree resulting in diffuse multifocal stricture formation leading to biliary cirrhosis, portal hypertension and liver failure. PSC is a life-threatening and debilitating disease. The median survival from diagnosis in symptomatic patients with PSC has been estimated to be 12 years.
MedDRA version: 17.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Product Name: LUM001
INN or Proposed INN: LUM001
Lumena Pharmaceuticals LLCNULLNot RecruitingFemale: yes
Male: yes
20Phase 2United States;United Kingdom
2NCT02061540
(ClinicalTrials.gov)
March 201411/2/2014Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing CholangitisA Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing CholangitisPrimary Sclerosing Cholangitis (PSC)Drug: LUM001Mirum Pharmaceuticals, Inc.NULLCompleted18 Years80 YearsAll27Phase 2United States;Canada;United Kingdom